Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Moonlake's Sonelokimab Falls Short in Hidradenitis Suppurativa Trials, Shares Plummet

Moonlake Immunotherapeutics faced a significant setback as its experimental immune disease drug, sonelokimab, failed to meet investor expectations in two pivotal late-stage clinical trials for hidradenitis suppurativa (HS). The disappointing results led to a dramatic 80% drop in the company's share price, erasing more than four-fifths of its market value.

NoahAI News9/30/2025

AstraZeneca Shifts Focus to US with NYSE Listing Amid Industry Pullback from Britain

AstraZeneca, the British-Swedish pharmaceutical giant, has announced plans to list its shares directly on the New York Stock Exchange (NYSE) in a move that signals a growing focus on the US market. This decision comes at a time when multiple drugmakers are reducing their presence in Britain, raising concerns about the country's attractiveness to the pharmaceutical industry.

NoahAI News9/30/2025

IO Biotech Faces Setback as FDA Halts Cancer Vaccine Approval Plans

IO Biotech, a company developing innovative cancer vaccines, has encountered a significant obstacle in its pursuit of regulatory approval for its lead candidate, Cylembio. The setback has led to substantial workforce reductions and a reevaluation of the company's strategic direction.

NoahAI News9/30/2025

Enanta's RSV Drug Misses Primary Endpoint in Phase 2b Trial, but Shows Promise in Secondary Analyses

Enanta Pharmaceuticals has reported mixed results from a phase 2b trial of its oral, direct-acting antiviral drug candidate, zelicapavir, for the treatment of respiratory syncytial virus (RSV). While the study failed to meet its primary endpoint, secondary analyses and subgroup data have provided encouraging signals that may support further development.

NoahAI News9/30/2025

MoonLake's IL-17 Drug Faces Setback in Phase 3 HS Trial, Stock Plummets

MoonLake Immunotherapeutics experienced a significant setback as its investigational interleukin-17 (IL-17) inhibitor, sonelokimab, missed the primary endpoint in one of two identical phase 3 studies for moderate to severe hidradenitis suppurativa (HS). The news sent the company's stock price into a tailspin, dropping 87% in premarket trading on Monday.

NoahAI News9/30/2025

Crystalys Therapeutics Emerges with $205M Series A to Advance Gout Treatment

Crystalys Therapeutics, a San Diego-based biotech company, has burst onto the scene with a substantial $205 million Series A financing round, signaling a significant development in the treatment of gout. The company, founded in 2022, is leveraging its experienced leadership team and a promising drug candidate to address unmet needs in gout therapy.

NoahAI News9/30/2025

Merck's Winrevair Shows Promising Results in Pulmonary Arterial Hypertension Treatment

Merck's pulmonary arterial hypertension (PAH) drug Winrevair has demonstrated significant efficacy in recent clinical trials, potentially revolutionizing treatment options for patients with this rare and progressive condition.The phase 3 Hyperion study, involving 320 recently diagnosed PAH patients, has shown that Winrevair, when combined with background therapy, reduced the risk of clinical worsening events by 76% compared to placebo. Only 11% of patients receiving Winrevair experienced a clinically worsening event, contrasting sharply with 37% in the placebo group.

NoahAI News9/30/2025

Softgel Formulations: Enhancing Drug Performance and Stability in Pharmaceutical Development

In an increasingly competitive pharmaceutical landscape, drug developers are turning to innovative formulation techniques to maximize the efficacy and stability of their therapeutics. Softgel and lipid-based formulations have emerged as powerful tools in this pursuit, offering solutions to common challenges such as poor solubility, bioavailability, and stability.

NoahAI News9/30/2025

FDA Actions in September: Keytruda Advances, Rare Disease Wins, and SMA Setbacks

September proved to be a pivotal month for the pharmaceutical industry, with the U.S. Food and Drug Administration (FDA) issuing a series of significant decisions that will shape the landscape of drug development and patient care. From bolstering the future of a blockbuster cancer drug to addressing ultra-rare diseases, the agency's actions have far-reaching implications for patients, healthcare providers, and pharmaceutical companies alike.

NoahAI News9/30/2025

FDA Decisions and Clinical Trials Shape Q4 Pharmaceutical Landscape

As the pharmaceutical industry enters the final quarter of 2025, a series of highly anticipated FDA decisions and clinical trial results are poised to significantly impact treatment landscapes across multiple therapeutic areas. From potential comebacks to groundbreaking firsts, Q4 promises to be a pivotal period for several key players in the sector.

NoahAI News9/30/2025

Siemens Healthineers Expands Robotics Portfolio with Micromate Partnership

Siemens Healthineers, a global leader in medical technology, has announced a strategic partnership with Interventional Systems to co-market the innovative Micromate robot for angiography suites. This collaboration marks Siemens Healthineers' second venture into the robotics space this month, signaling a significant push towards advanced medical automation.

NoahAI News9/30/2025

Biolinq Secures FDA De Novo Nod for Novel Intradermal Glucose Sensor

In a significant development for diabetes management technology, Biolinq has received FDA de novo classification for its innovative continuous glucose monitor (CGM) designed for individuals with Type 2 diabetes who do not require insulin. The device, named Biolinq Shine, represents a breakthrough in CGM technology, offering a needle-free approach to glucose monitoring.

NoahAI News9/27/2025

«1...43 44 45...67 »